← All trials
NCT06799884
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 18, 2025
- Primary completion
- Feb 21, 2025
- Completion date
- Feb 21, 2025
- First posted
- Jan 29, 2025
- Last posted
- Mar 11, 2025
- Enrollment
- 19
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Idorsia Pharmaceuticals Ltd.Lead sponsor
- Idorsia Pharmaceuticals Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.